var data={"title":"Sulfacetamide (ophthalmic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sulfacetamide (ophthalmic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390432?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sulfacetamide-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Sulfacetamide (ophthalmic): Drug information&quot;</a> and <a href=\"topic.htm?path=sulfacetamide-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sulfacetamide (ophthalmic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523096\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bleph-10</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523097\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>AK Sulf Liq;</li>\n      <li>Bleph 10 DPS;</li>\n      <li>Diosulf;</li>\n      <li>PMS-Sulfacetamide;</li>\n      <li>Sodium Sulamyd</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527189\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Ophthalmic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Sulfonamide Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527199\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sulfacetamide-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Sulfacetamide (ophthalmic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conjunctivitis:</b> Infants &ge;2 months, Children, and Adolescents: Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ointment: Instill <sup>1</sup>/<sub>2</sub> inch ribbon into the lower conjunctival sac of affected eye(s) every 3 to 4 hours and at bedtime; increase dosing interval as condition responds. Ointment may be used as an adjunct to the solution; usual duration of treatment: 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: Instill 1 to 2 drops into the lower conjunctival sac of affected eye(s) every 2 to 3 hours initially; increase dosing interval as condition responds; usual duration of treatment: 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trachoma:</b> Infants &ge;2 months, Children, and Adolescents: Ophthalmic: Solution: Instill 2 drops into the conjunctival sac of affected eye(s) every 2 hours; must be used in conjunction with systemic therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conjunctivitis, other superficial ocular infections: Note:</b> Taper dose by increasing dosage time interval as condition responds; usual duration of treatment: 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic solution: Instill 1 to 2 drops every 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ophthalmic ointment: Apply ~<sup>1</sup>/<sub>2 </sub>inch ribbon every 3 to 4 hours and at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trachoma:</b> Ophthalmic solution: Instill 2 drops every 2 hours; must be used in conjunction with systemic therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523211\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Ophthalmic, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (3.5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bleph-10: 10% (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (5 mL, 15 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523099\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527200\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For topical application to the eye only; not for injection. Avoid contact of tube or bottle tip with skin or eye. Apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops (Urtti 1993; Zimmerman 1982).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523156\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution: Store at 8&deg;C to 25&deg;C (46&deg;F to 77&deg;F); protect from light. Darkened solutions should not be used. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527190\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Ophthalmic: Treatment of conjunctivitis and other superficial ocular infections due to susceptible organisms (Ointment; solution: FDA approved in ages &ge;2 months and adults); adjunctive treatment with systemic sulfonamides for therapy of trachoma (Solution: FDA approved in ages &ge; 2 months and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523083\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bleph-10 may be confused with Blephamide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523149\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Systemic lupus erythematosus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Burning sensation of eyes, conjunctival hyperemia, conjunctivitis, corneal ulcer, eye irritation, stinging of eyes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523134\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sulfonamides or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for sulfonamides is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523135\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood dyscrasias: Severe reactions (rare fatalities), including agranulocytosis, aplastic anemia, and other blood dyscrasias, have occurred with sulfonamides (regardless of route). Discontinue at the first sign of serious reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatologic reactions: Severe reactions (rare fatalities), including Stevens-Johnson syndrome and toxic epidermal necrolysis, have occurred with sulfonamides (regardless of route). Discontinue at first sign of rash.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic necrosis: Fatalities (rare) associated with fulminant hepatic necrosis have occurred with sulfonamides (regardless of route). Discontinue at first sign of serious reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:2em;text-align:justify;\">&bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:2em;text-align:justify;\">&bull; Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms, including fungi. If superinfection is suspected, institute appropriate alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Do not use concurrently with silver preparations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: For topical application to the eye only; not for injection. To avoid contamination, do not touch tip of container to any surface.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Efficacy: May be inactivated by purulent exudates containing PABA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300089\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523151\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16049&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523129\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523130\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Use of systemic sulfonamides during pregnancy may cause kernicterus in the newborn.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527201\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Response to therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523166\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46149302\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Onset of action: Improvement of conjunctivitis is usually seen within 3 to 6 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523213\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Sulfacetamide Sodium Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (3.5 g): $65.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bleph-10 Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (5 mL): $159.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sulfacetamide Sodium Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (15 mL): $55.65</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059484\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acetopt (NZ);</li>\n      <li>Albucid (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, ID, IN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Antebor (BE);</li>\n      <li>Apisulfa (BH, QA, SA);</li>\n      <li>Apisulpha-20 (AE);</li>\n      <li>Blef-10 (CO, PE);</li>\n      <li>Blef-10 con lagrifilm (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Bleph-10 (AE, AU, BB, BH, CY, EG, IQ, IR, JO, KW, LB, LY, NZ, OM, QA, SA, SY, YE);</li>\n      <li>Bleph-30 (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Dermaseb (AR);</li>\n      <li>Dermaser (PY);</li>\n      <li>Isopto Cetamide (AE, BE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Locula (IN);</li>\n      <li>Optal (TH);</li>\n      <li>Opthmid (TR);</li>\n      <li>Paraqueimol (BR);</li>\n      <li>Riacetamid (AE);</li>\n      <li>Sulfacet Sodium (VE);</li>\n      <li>SulfacidE (IL);</li>\n      <li>Sulfaclan (KR);</li>\n      <li>SUlfatsil (UA);</li>\n      <li>Sulfex (HK, SG);</li>\n      <li>Synsul (CO);</li>\n      <li>Vitasul (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bleph-10 (sulfacetamide) [prescribing information]. Irvine, CA: Allergan; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sulfacetamide Sodium [prescribing information]. Minneapolis, MN: Perrigo; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed\" target=\"_blank\" id=\"8100087\">8100087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984;102(4):551-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-ophthalmic-pediatric-drug-information/abstract-text/6704011/pubmed\" target=\"_blank\" id=\"6704011\">6704011</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16049 Version 91.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9523096\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9523097\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10527189\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10527199\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9523211\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9523099\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10527200\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9523156\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10527190\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9523083\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9523149\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9523134\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9523135\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300089\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9523151\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9523129\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9523130\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10527201\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9523166\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F46149302\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9523213\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059484\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16049|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sulfacetamide-ophthalmic-drug-information\" class=\"drug drug_general\">Sulfacetamide (ophthalmic): Drug information</a></li><li><a href=\"topic.htm?path=sulfacetamide-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">Sulfacetamide (ophthalmic): Patient drug information</a></li></ul></div></div>","javascript":null}